P03372

※ Protein Information

Tag	Content
UniProt Accession	ESR1_HUMAN; P03372;
Entrez ID	2099
GenBank Protein ID	NM_000125.3; NM_001122740.1; NM_001122741.1; NM_001122742.1; NM_001291230.1; NM_001291241.1; NM_001328100.1; XM_006715375.3; XM_011535543.2; XM_011535544.2; XM_011535545.2; XM_017010376.1; XM_017010377.1; XM_017010378.1; XM_017010379.1; XM_017010380.1; XM_017010381.1;
GenBank Nucleotide ID	NP_000116.2; NP_001116212.1; NP_001116213.1; NP_001116214.1; NP_001278159.1; NP_001278170.1; NP_001315029.1; XP_006715438.1; XP_011533845.1; XP_011533846.1; XP_011533847.1; XP_016865865.1; XP_016865866.1; XP_016865867.1; XP_016865868.1; XP_016865869.1; XP_016865870.1;
Protein Name	Estrogen receptor (ER) (ER-alpha) (Estradiol receptor) (Nuclear receptor subfamily 3 group A member 1)
Gene Name	ESR1; ESR; NR3A1
Organism	Homo sapiens
NCBI Taxa ID	9606
Functional Description	Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequ(view all) Functional Description Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Isoform 3 is involved in activation of NOS3 and endothelial nitric oxide production. Isoforms lacking one or several functional domains are thought to modulate transcriptional activity by competitive ligand or DNA binding and/or heterodimerization with the full-length receptor. Essential for MTA1-mediated transcriptional regulation of BRCA1 and BCAS3. Isoform 3 can bind to ERE and inhibit isoform 1.
Sequence (Fasta)	MTMTLHTKAS GMALLHQIQG NELEPLNRPQ LKIPLERPLG EVYLDSSKPA VYNYPEGAAY 60 EFNAAAAANA QVYGQTGLPY GPGSEAAAFG SNGLGGFPPL NSVSPSPLML LHPPPQLSPF 120 LQPHGQQVPY YLENEPSGYT VREAGPPAFY RPNSDNRRQG GRERLASTND KGSMAMESAK 180 ETRYCAVCND YASGYHYGVW SCEGCKAFFK RSIQGHNDYM CPATNQCTID KNRRKSCQAC 240 RLRKCYEVGM MKGGIRKDRR GGRMLKHKRQ RDDGEGRGEV GSAGDMRAAN LWPSPLMIKR 300 SKKNSLALSL TADQMVSALL DAEPPILYSE YDPTRPFSEA SMMGLLTNLA DRELVHMINW 360 AKRVPGFVDL TLHDQVHLLE CAWLEILMIG LVWRSMEHPG KLLFAPNLLL DRNQGKCVEG 420 MVEIFDMLLA TSSRFRMMNL QGEEFVCLKS IILLNSGVYT FLSSTLKSLE EKDHIHRVLD 480 KITDTLIHLM AKAGLTLQQQ HQRLAQLLLI LSHIRHMSNK GMEHLYSMKC KNVVPLYDLL 540 LEMLDAHRLH APTSRGGASV EETDQSHLAT AGSTSSHSLQ KYYITGEAEG FPATV 596 Fasta Sequence >P03372\|ESR1; ESR; NR3A1\|Homo sapiens (Human) MTMTLHTKASGMALLHQIQGNELEPLNRPQLKIPLERPLGEVYLDSSKPAVYNYPEGAAYEFNAAAAANAQVYGQTGLPYGPGSEAAAFGSNGLGGFPPLNSVSPSPLMLLHPPPQLSPFLQPHGQQVPYYLENEPSGYTVREAGPPAFYRPNSDNRRQGGRERLASTNDKGSMAMESAKETRYCAVCNDYASGYHYGVWSCEGCKAFFKRSIQGHNDYMCPATNQCTIDKNRRKSCQACRLRKCYEVGMMKGGIRKDRRGGRMLKHKRQRDDGEGRGEVGSAGDMRAANLWPSPLMIKRSKKNSLALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADRELVHMINWAKRVPGFVDLTLHDQVHLLECAWLEILMIGLVWRSMEHPGKLLFAPNLLLDRNQGKCVEGMVEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHIHRVLDKITDTLIHLMAKAGLTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKCKNVVPLYDLLLEMLDAHRLHAPTSRGGASVEETDQSHLATAGSTSSHSLQKYYITGEAEGFPATV

※ PTM-Disease Association

Num	PTM	Disease	Cell Type	Type	PTM Site	PMID
1	Ubiquitination	Breast cancer/tumor/carcinoma		P		24125069
1	[Reference]: Histone acetyltransferase Hbo1 destabilizes estrogen receptor by ubiquitination and modulates proliferation of breast cancers
2	Methylation	Breast cancer/tumor/carcinoma		P		2733079; 18647968
2	[Reference]: Quantitative multiplex methylation-specific PCR of 11 genes involved in breast carcinogenesis (RARB, RASSF1, TWIST1, CCND2, ESR1, SCGB3A1, BRCA1, BRCA2, CDKN2A, APC, CDH1) was carried out on 32 BRCA1-associated and 46 sporadic breast carcinomas and on normal breast tissue from seven BRCA1 mutation carriers and 13 non-carriers.
3	Serine Phosphorylation	Breast cancer/tumor/carcinoma	MCF-7 cell line	P	S	22733972
3	[Reference]: Stable inhibition of specific estrogen receptor (ER) phosphorylation confers increased growth, migration/invasion, and disruption of estradiol signaling in MCF-7 breast cancer cells
4	Serine Phosphorylation	Breast cancer/tumor/carcinoma	MCF-7 cell line	P	S	24051437; 22733972; 23946788
4	[Reference]: Stable inhibition of specific estrogen receptor (ER) phosphorylation confers increased growth, migration/invasion, and disruption of estradiol signaling in MCF-7 breast cancer cells
5	Methylation	Breast cancer/tumor/carcinoma		U		3917730; 24649078
5	[Reference]: These results suggested that estrogens may modulate CTCF expression, although there was no apparent association between ERs and CTCFL.
6	Tyrosine Phosphorylation	Breast cancer/tumor/carcinoma		U	Y52	20101225
6	[Reference]: The ERalpha (Y52,219F) mutant shows reduced breast cancer cell growth and invasion. Taken together, these results show that c-Abl is a novel kinase that upregulates ERalpha expression and promotes breast cancer cell proliferation, suggesting a great potential for this kinase to function as a therapeutic target for breast cancer.
7	Serine Phosphorylation	Breast cancer/tumor/carcinoma	MCF-7 cell line	U	S104	20418363; 19104930
7	[Reference]: A phosphorylation code for oestrogen receptor-alpha predicts clinical outcome to endocrine therapy in breast cancer.
8	Serine Phosphorylation	Breast cancer/tumor/carcinoma		U	S106	20418363; 19104930
8	[Reference]: S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered "good" factors. T311 and S559 have a HR > 1 are considered "bad" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. ;
9	Serine Phosphorylation	Endometrial cancer/carcinoma	cell line	P	S118	23530112
9	[Reference]: The phosphorylated ER induces gene transcription manifested by enhanced cell proliferation and survival.
10	Serine Phosphorylation	Breast cancer/tumor/carcinoma		U	S118	16168121; 20418363; 19940281; 12118371; 19104930
10	[Reference]: S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered "good" factors. T311 and S559 have a HR > 1 are considered "bad" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. ;;;High S118 ER-alpha phosphorylation is found in some breast cancer tumors.
11	Serine Phosphorylation	Endometrial cancer/carcinoma	cell line	P	S167	23530112
11	[Reference]: The phosphorylated ER induces gene transcription manifested by enhanced cell proliferation and survival.
12	Serine Phosphorylation	Breast cancer/tumor/carcinoma		U	S167	16168121; 19940156; 24166501; 20418363; 19104930; 17157789
12	[Reference]: High S167 phosphorylation in tamoxifen resistant tumors;S104/6, S118, S167, S282 and S294 have S167/S305 and Ser167 alone, but not Ser305 phosphorylation, are significantly associated disease-free survival in breast cancer patients
13	Tyrosine Phosphorylation	Breast cancer/tumor/carcinoma		U	Y219	20101225
13	[Reference]: The ERalpha (Y52,219F) mutant shows reduced breast cancer cell growth and invasion. Taken together, these results show that c-Abl is a novel kinase that upregulates ERalpha expression and promotes breast cancer cell proliferation, suggesting a great potential for this kinase to function as a therapeutic target for breast cancer.
14	Arginine Methylation	Breast cancer/tumor/carcinoma		U	R260	20116391
14	[Reference]: Ralpha is methylated in normal epithelial breast cells and is hypermethylated in a subset of breast cancers
15	Lysine Methylation	Breast cancer/tumor/carcinoma		P	K266	23856582; 24101509; 23235912
15	[Reference]: ER is methylated in breast biopsies, and the interaction of PRMT1 with the AML1??TO fusion protein promotes leukemic cell proliferation
16	Serine Phosphorylation	Breast cancer/tumor/carcinoma		U	S294	20418363; 19104930
16	[Reference]: S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered "good" factors. T311 and S559 have a HR > 1 are considered "bad" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. ;
17	Monoubiquitination	Breast cancer/tumor/carcinoma		P	K302/303	21356307
17	[Reference]: 17-Estradiol-induced cell proliferation requires estrogen receptor (ER) monoubiquitination
18	Lysine Methylation	Breast cancer/tumor/carcinoma		P	K302	21680538
18	[Reference]: Monomethylation of ERalpha at K302 is mediated by SET7 lysine methyltransferase; this modification acts on ERalpha stability and facilitates the recruitment of ER to its target genes for their transactivation.
19	Acetylation	Breast cancer/tumor/carcinoma		N	K303	15604293
19	[Reference]: Mutation of this phosphorylation site to aspartic acid to mimic constitutive phosphorylation blocks acetylation of the K303 ERalpha site and generates an enhanced transcriptional response similar to that seen with the naturally occurring K303R mutant receptor.
20	Serine Phosphorylation	Breast cancer/tumor/carcinoma		U	S305	26272591; 24166501; 15193262; 20179234
20	[Reference]: Estrogen receptor-alpha phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer.
21	Threonine Phosphorylation	Breast cancer/tumor/carcinoma		U	T311	20418363; 19104930
21	[Reference]: S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered "good" factors. T311 and S559 have a HR > 1 are considered "bad" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. ;
22	Tyrosine Phosphorylation	Breast cancer/tumor/carcinoma		N	Y537	21680538
22	[Reference]: For example, the Y537N mutant (phosphorylated site) identified in tumors of metastatic breast cancer patients has been shown to confer a constitutive transactivation function to the receptor.
23	Serine Phosphorylation	Breast cancer/tumor/carcinoma		U	S559	20418363; 19104930
23	[Reference]: S104/6, S118, S167, S282 and S294 have a hazard ratio (HR) < 1 are considered "good" factors. T311 and S559 have a HR > 1 are considered "bad" factors. Sum of individual scores give P7-ER-alpha scores. Lowere scores indicate better outcomes. ;

※ Disease Cross-ref Annotation

Database	Annotation
Cancer Gene Census	breast
CTD (Curated) (count: 38) (view all)	MESH:D000230 ; Adenocarcinoma MESH:D000544 ; Alzheimer Disease MESH:D001254 ; Astrocytoma MESH:D050197 ; Atherosclerosis MESH:D001851 ; Bone Diseases, Metabolic MESH:D001943 ; Breast Neoplasms MESH:D002277 ; Carcinoma MESH:D006528 ; Carcinoma, Hepatocellular MESH:D002471 ; Cell Transformation, Neoplastic MESH:D003324 ; Coronary Artery Disease MESH:D004195 ; Disease Models, Animal MESH:D018450 ; Disease Progression MESH:D016889 ; Endometrial Neoplasms MESH:D052776 ; Female Urogenital Diseases MESH:D005262 ; Feminization MESH:D005921 ; Glomerulonephritis MESH:D007247 ; Infertility, Female MESH:D007248 ; Infertility, Male MESH:D007889 ; Leiomyoma MESH:D007938 ; Leukemia MESH:D008113 ; Liver Neoplasms MESH:D008175 ; Lung Neoplasms MESH:D015674 ; Mammary Neoplasms, Animal MESH:D008325 ; Mammary Neoplasms, Experimental MESH:D008654 ; Mesothelioma MESH:D008881 ; Migraine Disorders OMIM:157300 ; MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 1 MESH:D059352 ; Musculoskeletal Pain MESH:D009203 ; Myocardial Infarction MESH:D009361 ; Neoplasm Invasiveness MESH:D009362 ; Neoplasm Metastasis MESH:D009364 ; Neoplasm Recurrence, Local MESH:D009765 ; Obesity MESH:D009845 ; Oligospermia MESH:D019048 ; Prostatic Intraepithelial Neoplasia MESH:D011471 ; Prostatic Neoplasms MESH:D011605 ; Psychoses, Substance-Induced MESH:D001749 ; Urinary Bladder Neoplasms
DisGeNet (Curated) (count: 69) (view all)	C0000889; Acanthosis Nigricans C0001418; Adenocarcinoma C0002395; Alzheimer's Disease C0004114; Astrocytoma C0004153; Atherosclerosis C0005586; Bipolar Disorder C0005695; Bladder Neoplasm C0005944; Metabolic Bone Disorder C0007621; Neoplastic Cell Transformation C0010054; Coronary Arteriosclerosis C0011570; Mental Depression C0011581; Depressive disorder C0014170; Endometrial Neoplasms C0015799; Feminization C0017658; Glomerulonephritis C0020459; Hyperinsulinism C0021361; Female infertility C0021364; Male infertility C0023267; Fibroid Tumor C0023418; leukemia C0023903; Liver neoplasms C0024121; Lung Neoplasms C0024667; Animal Mammary Neoplasms C0024668; Mammary Neoplasms, Experimental C0024809; Marijuana Abuse C0025500; Mesothelioma C0026858; Musculoskeletal Pain C0027051; Myocardial Infarction C0027627; Neoplasm Metastasis C0027643; Neoplasm Recurrence, Local C0028754; Obesity C0028960; Oligospermia C0029453; Osteopenia C0029456; Osteoporosis C0033578; Prostatic Neoplasms C0033941; Psychoses, Substance-Induced C0036341; Schizophrenia C0036939; Shared Paranoid Disorder C0149931; Migraine Disorders C0232939; Primary physiologic amenorrhea C0262527; intermittent abdominal pain C0266013; Congenital hypoplasia of breast C0266399; Infantile uterus C0271650; Impaired glucose tolerance C0282612; Prostatic Intraepithelial Neoplasias C0525045; Mood Disorders C0541764; Delayed bone age C0702166; Acne C0747078; Generalized osteopenia C1458155; Mammary Neoplasms C1720887; Female Urogenital Diseases C1846228; Absence of pubertal development C1849265; Overgrowth C1851731; Generalized overgrowth C1862265; Elevated gonadotropins C1865200; Delayed epiphyseal ossification C1868549; Marked delay in bone age C1956346; Coronary Artery Disease C2239176; Liver carcinoma C3150281; Fetal overgrowth C3808022; Abdominal pain, episodic C3809250; ESTROGEN RESISTANCE C3887485; MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 1 C4020899; Autosomal recessive predisposition C4021240; Elevated tissue non-specific alkaline phosphatase C4021551; Absence of secondary sex characteristics C4024641; Enlarged polycystic ovaries C4280506; Plaque build-up in arteries supplying blood to heart C4280565; Delayed maturation of end part of long bone
HGMD (count: 16) (view all)	CE086654; Osteoporosis, association with; Repeat variations CX952016; Osteoporosis, association with; Repeat variations CE067330; Reduced spermatogenesis in infertile men, assoc.; Repeat variations CE057923; Endothelial fibrinolytic regulation, assoc. wilth; Repeat variations CG084474; Infertility, male, association with; Gross deletions CG081034; Cleft lip and palate ?; Gross deletions CM940378; Oestrogen resistance; Missense/nonsense CM016135; Osteoporosis; Missense/nonsense CM016108; Lower femoral neck BMD, association with; Missense/nonsense CM057965; Precocious puberty; Missense/nonsense CM056948; Systemic lupus erythematosus, risk, assoc. with ?; Missense/nonsense CR083998; Increased HDL cholesterol, association with; Regulatory CR093128; Transcriptional regulation, assoc. with ; Regulatory CR078145; Gene expression, association with; Regulatory CR076697; Left ventricular hypertrophy, association with ?; Regulatory CS024443; Increased HDL cholesterol after HRT, assoc. with; Splicing
GWASdb (count: 144) (view all)	rs2941740; Bone mineral density (hip); bone resorption disease rs2941740; Breast cancer; breast cancer rs3020333; Bone mineral density (spine); bone resorption disease rs2982573; Bone mineral density (spine); bone resorption disease rs2982573; Breast cancer; breast cancer rs2982572; Breast cancer; breast cancer rs2982571; Bone mineral density (spine); bone resorption disease rs2982571; Breast cancer; breast cancer rs3020334; Bone mineral density (spine); bone resorption disease rs3020334; Breast cancer; breast cancer rs2941742; Breast cancer; breast cancer rs3020335; Bone mineral density (spine); bone resorption disease rs3020335; Breast cancer; breast cancer rs2982570; Bone mineral density (spine); bone resorption disease rs2982570; Breast cancer; breast cancer rs3020336; Breast cancer; breast cancer rs1293936; Bone mineral density (spine); bone resorption disease rs1293935; Breast cancer; breast cancer rs851985; Breast cancer; breast cancer rs851984; Breast cancer; breast cancer rs851983; Breast cancer; breast cancer rs851982; Bone mineral density (spine); bone resorption disease rs851982; Breast cancer; breast cancer rs9383591; Breast cancer; breast cancer rs851980; Coronary Artery Disease; coronary artery disease rs8180576; Breast cancer; breast cancer rs12525163; Endometriosis; endometriosis rs12525163; Breast cancer; breast cancer rs1159327; Endometriosis; endometriosis rs2982565; Coronary Artery Disease; coronary artery disease rs6899458; Type 2 diabetes; type 2 diabetes mellitus rs6899458; Coronary Artery Disease; coronary artery disease rs2982562; Bone mineral density (spine); bone resorption disease rs2982561; Bone mineral density (spine); bone resorption disease rs3020343; Bone mineral density (spine); bone resorption disease rs3020343; Endometriosis; endometriosis rs2982560; Bone mineral density (spine); bone resorption disease rs2982558; Bone mineral density (spine); bone resorption disease rs201941147; Bone mineral density (spine); bone resorption disease rs2982557; Bone mineral density (spine); bone resorption disease rs2982556; Bone mineral density (spine); bone resorption disease rs3020348; Bone mineral density (spine); bone resorption disease rs3020348; Endometriosis; endometriosis rs2982554; Bone mineral density (spine); bone resorption disease rs3020349; Bone mineral density (spine); bone resorption disease rs3020300; Bone mineral density (spine); bone resorption disease rs2982552; Bone mineral density (spine); bone resorption disease rs2982552; Bone properties (heel); osteoporosis rs2982551; Bone mineral density (spine); bone resorption disease rs2982551; Breast cancer; breast cancer rs2982550; Breast cancer; breast cancer rs3020301; Bone mineral density (spine); bone resorption disease rs3020301; Breast cancer; breast cancer rs1415194; Bone mineral density (spine); bone resorption disease rs1999807; Bone mineral density (spine); bone resorption disease rs3020304; Bone mineral density (spine); bone resorption disease rs3020306; Bone mineral density (spine); bone resorption disease rs3020307; Bone mineral density (spine); bone resorption disease rs9397445; Breast cancer; breast cancer rs1856057; Bone mineral density (spine); bone resorption disease rs1999805; Bone mineral density (spine); bone resorption disease rs1999805; Breast cancer; breast cancer rs3020308; Bone mineral density (spine); bone resorption disease rs2982575; Bone mineral density (spine); bone resorption disease rs2982575; Lumbar spine bone mineral density (premenopausal); bone resorption disease rs2982575; Femoral neck bone mineral density (premenopausal); bone resorption disease rs2152750; Bone mineral density (spine); bone resorption disease rs9322330; Breast cancer; breast cancer rs2982567; Bone mineral density (spine); bone resorption disease rs11155811; Bone mineral density (spine); bone resorption disease rs11155812; Breast cancer; breast cancer rs4644077; Breast cancer; breast cancer rs1124674; Bone mineral density (spine); bone resorption disease rs60945108; Obesity-related traits; obesity rs1336981; Bone mineral density (spine); bone resorption disease rs9371551; Breast cancer; breast cancer rs9371551; Smoking cessation; nicotine dependence rs73780860; Obesity-related traits; obesity rs9479107; Breast cancer; breast cancer rs2504071; Bone mineral density (spine); bone resorption disease rs1890010; Bone mineral density (spine); bone resorption disease rs2504069; Bone mineral density (spine); bone resorption disease rs118028050; Breast cancer; breast cancer rs2504063; Bone mineral density (spine); bone resorption disease rs2504063; Bone mineral density; bone resorption disease rs1415193; Bone mineral density (spine); bone resorption disease rs2504065; Bone mineral density (spine); bone resorption disease rs543650; Height; Null rs79994281; Breast cancer; breast cancer rs488133; Height; Null rs867239; Breast cancer; breast cancer rs6914438; Breast cancer; breast cancer rs532010; Non-alcoholic fatty liver disease histology (other); fatty liver disease rs12660738; Breast cancer; breast cancer rs6920483; Breast cancer; breast cancer rs3778609; Breast cancer; breast cancer rs3778610; Breast cancer; breast cancer rs13362642; Breast cancer; breast cancer rs9479121; Breast cancer; breast cancer rs9479122; Breast cancer; breast cancer rs12523770; Breast cancer; breast cancer rs12523805; Breast cancer; breast cancer rs7771894; Breast cancer; breast cancer rs9479126; Breast cancer; breast cancer rs7753153; Intelligence; attention deficit hyperactivity disorder\|cognitive disorder rs17081740; Multiple complex diseases; Null rs12527007; Breast cancer; breast cancer rs6909023; vWF levels, in plasma; von Willebrand's disease\|factor VIII deficiency\|vein disease rs6937568; vWF levels, in plasma; von Willebrand's disease\|factor VIII deficiency\|vein disease rs28457010; Breast cancer; breast cancer rs6902771; Alcohol dependence; alcohol dependence rs3853251; Self-reported allergy; hypersensitivity reaction disease rs9322331; Self-reported allergy; hypersensitivity reaction disease rs2234693; Smoking initiation; nicotine dependence rs9340799; Drug response to Tamoxifen; Null rs9340799; Self-reported allergy; hypersensitivity reaction disease rs3936674; Self-reported allergy; hypersensitivity reaction disease rs9322336; Blood pressure, CVD RF and other traits (body mass index (BMI), waist:hip ratio, renin activity in plasma, aldosterone concentration in plasma, BNP levels in plasma, alcohol consumption); hypertension rs11155820; Multiple complex diseases; Null rs2347867; Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs); neutropenia rs9397453; Multiple complex diseases; Null rs9340907; LDL cholesterol; atherosclerosis\|coronary artery disease rs9340907; Cholesterol, total; coronary artery disease\|lipid metabolism disorder\|arteriosclerosis rs2982694; Sudden cardiac arrest; coronary artery disease rs9340922; Triglycerides; coronary artery disease\|lipid metabolism disorder\|arteriosclerosis rs9383951; Breast cancer; breast cancer rs7768330; Triglycerides; coronary artery disease\|lipid metabolism disorder\|arteriosclerosis rs726281; Lung function (forced vital capacity); lung disease rs726281; Body Mass Index; obesity rs9340941; Asthma; asthma rs9340953; Cholesterol, total; coronary artery disease\|lipid metabolism disorder\|arteriosclerosis rs2207232; Response to taxane treatment (placlitaxel); lung cancer rs9340996; Triglycerides; coronary artery disease\|lipid metabolism disorder\|arteriosclerosis rs2982712; Height; Null rs9341023; LDL cholesterol; atherosclerosis\|coronary artery disease rs9341023; HDL cholesterol; cholesterol ester storage disease\|cholesterol embolism\|coronary artery disease rs9341023; Cholesterol, total; coronary artery disease\|lipid metabolism disorder\|arteriosclerosis rs9341023; Triglycerides; coronary artery disease\|lipid metabolism disorder\|arteriosclerosis rs9341059; LDL cholesterol; atherosclerosis\|coronary artery disease rs9341059; HDL cholesterol; cholesterol ester storage disease\|cholesterol embolism\|coronary artery disease rs3798577; Height; Null rs3798577; Lung function (forced vital capacity); lung disease rs9341074; Triglycerides; coronary artery disease\|lipid metabolism disorder\|arteriosclerosis rs3798757; HDL cholesterol; cholesterol ester storage disease\|cholesterol embolism\|coronary artery disease

※ PTM Sites

PTM	Modification Sites
Phosphorylation (count: 29) (view all)	10 MTLHTKASGMALLHQ dbPAF 102 GGFPPLNSVSPSPLM dbPAF 104 FPPLNSVSPSPLMLL dbPAF 106 PLNSVSPSPLMLLHP dbPAF 118 LHPPPQLSPFLQPHG dbPAF 154 PAFYRPNSDNRRQGG dbPAF 167 GGRERLASTNDKGSM dbPAF 2 ****MTMTLHTKA dbPAF 201 GYHYGVWSCEGCKAF dbPAF 212 CKAFFKRSIQGHNDY dbPAF 219 SIQGHNDYMCPATNQ dbPAF 236 IDKNRRKSCQACRLR dbPAF 282 EGRGEVGSAGDMRAA dbPAF 294 RAANLWPSPLMIKRS dbPAF 305 IKRSKKNSLALSLTA dbPAF 311 NSLALSLTADQMVSA dbPAF 341 TRPFSEASMMGLLTN dbPAF 4 MTMTLHTKASG dbPAF 46 LGEVYLDSSKPAVYN dbPAF 47 GEVYLDSSKPAVYNY dbPAF 485 VLDKITDTLIHLMAK dbPAF 52 DSSKPAVYNYPEGAA dbPAF 537 CKNVVPLYDLLLEML dbPAF 554 HRLHAPTSRGGASVE dbPAF 559 PTSRGGASVEETDQS dbPAF 576 ATAGSTSSHSLQKYY dbPAF 578 AGSTSSHSLQKYYIT dbPAF 594 EAEGFPATV**** dbPAF 7 *MTMTLHTKASGMAL dbPAF
Acetylation (count: 7) (view all)	266 RRGGRMLKHKRQRDD PLMD 268 GGRMLKHKRQRDDGE PLMD 299 WPSPLMIKRSKKNSL PLMD 302 PLMIKRSKKNSLALS PLMD 303 LMIKRSKKNSLALSL PLMD 472 TLKSLEEKDHIHRVL PLMD 8 MTMTLHTKASGMALL PLMD
Ubiquitination (count: 1)	302 PLMIKRSKKNSLALS PLMD
Sumoylation (count: 8) (view all)	171 RLASTNDKGSMAMES PLMD 180 SMAMESAKETRYCAV PLMD 266 RRGGRMLKHKRQRDD PLMD 268 GGRMLKHKRQRDDGE PLMD 299 WPSPLMIKRSKKNSL PLMD 302 PLMIKRSKKNSLALS PLMD 303 LMIKRSKKNSLALSL PLMD 472 TLKSLEEKDHIHRVL PLMD
Glycation (count: 1)	299 WPSPLMIKRSKKNSL PLMD
Methylation (count: 5)	171 RLASTNDKGSMAMES PLMD 180 SMAMESAKETRYCAV PLMD 266 RRGGRMLKHKRQRDD PLMD 302 PLMIKRSKKNSLALS PLMD 401 RSMEHPGKLLFAPNL PLMD

※ Protein-Protein Interaction

Network

Interaction

Source

A6NMY6	P03372	IntAct
A7YIJ8	P03372	IntAct
A8MXH5	P03372	BioGRID
E9PFC7	P03372	HPRD
F5GZX4	P03372	HPRD
F5H687	P03372	BioGRID
G3V0F8	P03372	HPRD
H0YCF7	P03372	BioGRID
H0YG33	P03372	IntAct
H7C2I1	P03372	HPRD
O00268	P03372	BioGRID
O00429	P03372	IntAct
O00567	P03372	IntAct
O00571	P03372	IntAct
O14686	P03372	HPRD; IntAct
O15042	P03372	IntAct
O15111	P03372	HPRD
O15164	P03372	HPRD; IntAct
O15440	P03372	IntAct
O15514	P03372	HPRD
O15523	P03372	IntAct
O43143	P03372	IntAct
O43251	P03372	IntAct;HPRD
O43390	P03372	IntAct
O43432	P03372	IntAct
O43524	P03372	HPRD
O43795	P03372	IntAct
O43815	P03372	HPRD
O43823	P03372	IntAct
O60506	P03372	IntAct
O60563	P03372	HPRD
O60832	P03372	IntAct
O60869	P03372	IntAct
O75110	P03372	IntAct
O75293	P03372	HPRD
O75369	P03372	IntAct
O75376	P03372	HPRD; IntAct
O75448	P03372	HPRD
O75475	P03372	IntAct
O75533	P03372	IntAct
O75925	P03372	HPRD; DIP
O75934	P03372	HPRD
O76021	P03372	IntAct
O94776	P03372	MINT
O94906	P03372	HPRD
O94989	P03372	HPRD
O94992	P03372	HPRD
O95232	P03372	IntAct
O95257	P03372	HPRD
O95793	P03372	IntAct
O95831	P03372	IntAct
P00533	P03372	HPRD; MINT;IntAct
P01160	P03372	HPRD
P02008	P03372	BioGRID
P02042	P03372	BioGRID
P02100	P03372	BioGRID
P02786	P03372	IntAct
P02787	P03372	IntAct
P03372	P03372	HPRD; BioGRID; IntAct
P03372	P04406	IntAct
P03372	P04626	HPRD
P03372	P04637	HPRD
P03372	P04843	IntAct
P03372	P04844	IntAct
P03372	P05089	IntAct
P03372	P05090	IntAct
P03372	P05109	IntAct
P03372	P05141	IntAct
P03372	P05186	BioGRID
P03372	P05388	IntAct
P03372	P05412	HPRD
P03372	P06239	HPRD
P03372	P06396	IntAct
P03372	P06401	HPRD
P03372	P06576	IntAct
P03372	P06748	IntAct
P03372	P07355	IntAct
P03372	P07900	HPRD
P03372	P07998	BioGRID
P03372	P08047	HPRD; IntAct
P03372	P08069	HPRD
P03372	P08238	HPRD
P03372	P08865	IntAct
P03372	P09651	IntAct
P03372	P09874	IntAct
P03372	P0CG47	IntAct
P03372	P10275	HPRD
P03372	P10276	HPRD
P03372	P10588	HPRD
P03372	P10589	HPRD
P03372	P10809	IntAct
P03372	P10827	HPRD
P03372	P10828	HPRD
P03372	P11021	IntAct
P03372	P11142	IntAct
P03372	P11387	IntAct
P03372	P11388	IntAct
P03372	P11474	HPRD
P03372	P11940	IntAct
P03372	P12814	IntAct
P03372	P12931	HPRD; DIP; MINT;IntAct
P03372	P13056	HPRD; IntAct
P03372	P14649	IntAct
P03372	P14859	HPRD
P03372	P14923	IntAct
P03372	P15848	IntAct
P03372	P15880	IntAct
P03372	P16104	IntAct
P03372	P16989	IntAct
P03372	P17275	HPRD
P03372	P17480	IntAct
P03372	P17535	HPRD
P03372	P17612	HPRD
P03372	P17676	HPRD; IntAct
P03372	P17844	HPRD; IntAct
P03372	P17861	HPRD
P03372	P18031	HPRD; MINT
P03372	P18124	IntAct
P03372	P18621	IntAct
P03372	P18846	IntAct
P03372	P19338	IntAct
P03372	P19793	HPRD
P03372	P19838	IntAct;HPRD
P03372	P20226	HPRD
P03372	P20290	IntAct
P03372	P21333	IntAct
P03372	P22415	HPRD
P03372	P22626	IntAct
P03372	P23396	IntAct
P03372	P23560	HPRD
P03372	P24385	HPRD
P03372	P25398	IntAct
P03372	P26368	IntAct
P03372	P26373	IntAct
P03372	P27361	HPRD
P03372	P27449	BioGRID
P03372	P27540	HPRD
P03372	P27635	IntAct
P03372	P27986	HPRD
P03372	P28065	MINT
P03372	P28482	HPRD
P03372	P29350	MINT
P03372	P29353	HPRD;IntAct
P03372	P29372	HPRD
P03372	P29375	HPRD
P03372	P29474	DIP
P03372	P30050	IntAct
P03372	P30305	HPRD
P03372	P31151	IntAct
P03372	P31749	HPRD
P03372	P31751	HPRD
P03372	P31947	IntAct
P03372	P32780	HPRD
P03372	P32969	IntAct
P03372	P33316	HPRD
P03372	P34931	IntAct
P03372	P34932	HPRD
P03372	P35222	HPRD
P03372	P35268	IntAct
P03372	P35579	IntAct
P03372	P35637	IntAct
P03372	P35659	IntAct
P03372	P35869	HPRD
P03372	P36578	IntAct
P03372	P36873	IntAct
P03372	P36956	HPRD
P03372	P37235	IntAct
P03372	P38159	IntAct
P03372	P38398	IntAct; MINT
P03372	P38646	IntAct
P03372	P38936	HPRD
P03372	P39023	IntAct
P03372	P40429	IntAct
P03372	P41235	HPRD
P03372	P42229	HPRD; MINT
P03372	P46013	IntAct
P03372	P46087	IntAct
P03372	P46776	IntAct
P03372	P46777	IntAct
P03372	P46778	IntAct
P03372	P46779	IntAct
P03372	P46781	IntAct
P03372	P46940	IntAct
P03372	P47756	IntAct
P03372	P47914	IntAct
P03372	P47929	IntAct
P03372	P48552	HPRD; IntAct
P03372	P48594	IntAct
P03372	P49116	HPRD
P03372	P49137	IntAct
P03372	P49756	BioGRID
P03372	P49790	IntAct
P03372	P49796	HPRD
P03372	P49815	HPRD
P03372	P50402	IntAct
P03372	P50454	IntAct
P03372	P50613	HPRD
P03372	P50914	IntAct
P03372	P51398	IntAct
P03372	P51531	HPRD
P03372	P51532	MINT
P03372	P51812	HPRD
P03372	P51843	HPRD
P03372	P51946	HPRD
P03372	P51948	HPRD
P03372	P51991	IntAct
P03372	P52272	IntAct
P03372	P52597	IntAct
P03372	P53041	IntAct
P03372	P53675	IntAct
P03372	P55345	HPRD; IntAct; MINT
P03372	P56945	HPRD
P03372	P58107	IntAct
P03372	P60468	IntAct
P03372	P60660	IntAct
P03372	P60709	IntAct
P03372	P60763	IntAct
P03372	P60842	IntAct
P03372	P60866	IntAct
P03372	P61158	IntAct
P03372	P61160	IntAct
P03372	P61247	IntAct
P03372	P61313	IntAct
P03372	P61371	HPRD
P03372	P61513	IntAct
P03372	P61626	IntAct
P03372	P61978	IntAct
P03372	P62136	IntAct
P03372	P62158	HPRD
P03372	P62195	HPRD
P03372	P62241	IntAct
P03372	P62244	IntAct
P03372	P62249	IntAct
P03372	P62263	IntAct
P03372	P62266	IntAct
P03372	P62269	IntAct
P03372	P62277	IntAct
P03372	P62280	IntAct
P03372	P62314	IntAct
P03372	P62424	IntAct
P03372	P62701	IntAct
P03372	P62750	IntAct
P03372	P62753	IntAct
P03372	P62847	IntAct
P03372	P62854	IntAct
P03372	P62873	IntAct
P03372	P62879	IntAct
P03372	P62906	IntAct
P03372	P62913	IntAct
P03372	P62917	IntAct
P03372	P62952	IntAct
P03372	P62993	HPRD
P03372	P63096	HPRD
P03372	P63279	HPRD
P03372	P67809	IntAct
P03372	P68032	IntAct
P03372	P68363	HPRD
P03372	P78317	HPRD
P03372	P78362	IntAct
P03372	P78527	IntAct
P03372	P82650	IntAct
P03372	P82673	IntAct
P03372	P82914	IntAct
P03372	P82932	IntAct
P03372	P82933	IntAct
P03372	P83111	IntAct
P03372	P83731	IntAct
P03372	P83881	IntAct
P03372	P84022	HPRD
P03372	P84098	IntAct
P03372	P84103	IntAct
P03372	P98177	HPRD
P03372	Q00056	BioGRID
P03372	Q00403	HPRD
P03372	Q00610	IntAct
P03372	Q00839	IntAct
P03372	Q00987	HPRD; IntAct
P03372	Q01082	IntAct
P03372	Q01130	IntAct
P03372	Q01780	IntAct
P03372	Q01844	IntAct
P03372	Q01851	HPRD
P03372	Q02413	IntAct
P03372	Q02447	HPRD; IntAct
P03372	Q02543	IntAct
P03372	Q02878	IntAct
P03372	Q02880	IntAct
P03372	Q03135	HPRD
P03372	Q03518	HPRD
P03372	Q04206	HPRD; IntAct
P03372	Q04637	IntAct
P03372	Q04917	HPRD
P03372	Q05086	DIP
P03372	Q05516	HPRD
P03372	Q06787	IntAct
P03372	Q07020	IntAct
P03372	Q07666	IntAct
P03372	Q07889	HPRD
P03372	Q07955	IntAct
P03372	Q08211	IntAct
P03372	Q08379	IntAct
P03372	Q09028	IntAct
P03372	Q09472	HPRD; DIP; IntAct
P03372	Q09666	IntAct
P03372	Q12756	HPRD
P03372	Q12778	HPRD; IntAct
P03372	Q12802	IntAct;HPRD
P03372	Q12837	HPRD
P03372	Q12905	IntAct
P03372	Q12906	IntAct
P03372	Q12962	HPRD
P03372	Q13029	HPRD
P03372	Q13045	HPRD
P03372	Q13093	IntAct
P03372	Q13105	HPRD; DIP
P03372	Q13151	IntAct
P03372	Q13153	HPRD
P03372	Q13233	MINT
P03372	Q13243	IntAct
P03372	Q13247	IntAct
P03372	Q13263	HPRD
P03372	Q13283	IntAct
P03372	Q13330	HPRD; MINT
P03372	Q13347	HPRD
P03372	Q13352	HPRD
P03372	Q13428	IntAct
P03372	Q13485	HPRD
P03372	Q13523	IntAct
P03372	Q13547	IntAct; MINT
P03372	Q13569	HPRD
P03372	Q13573	IntAct
P03372	Q13620	HPRD
P03372	Q13642	IntAct
P03372	Q13813	IntAct
P03372	Q13823	IntAct
P03372	Q13885	HPRD
P03372	Q14103	IntAct
P03372	Q14151	HPRD; IntAct
P03372	Q14157	IntAct
P03372	Q14192	HPRD
P03372	Q14444	IntAct
P03372	Q14498	HPRD; IntAct
P03372	Q14669	IntAct
P03372	Q14684	IntAct
P03372	Q14686	HPRD; IntAct
P03372	Q14764	HPRD
P03372	Q14839	IntAct
P03372	Q14980	IntAct
P03372	Q15029	IntAct
P03372	Q15149	IntAct
P03372	Q15185	HPRD
P03372	Q15291	IntAct
P03372	Q15418	HPRD
P03372	Q15424	HPRD
P03372	Q15466	HPRD
P03372	Q15596	HPRD; DIP; IntAct
P03372	Q15637	IntAct
P03372	Q15648	HPRD
P03372	Q15649	IntAct
P03372	Q15650	HPRD
P03372	Q15788	HPRD; IntAct; MINT
P03372	Q15796	HPRD
P03372	Q16539	HPRD
P03372	Q16576	IntAct
P03372	Q16629	IntAct
P03372	Q16643	IntAct
P03372	Q16665	IntAct
P03372	Q16698	IntAct
P03372	Q32P51	IntAct
P03372	Q33E94	HPRD
P03372	Q3L8U1	HPRD;IntAct
P03372	Q49A26	IntAct
P03372	Q4LE28	HPRD
P03372	Q5JTH9	IntAct
P03372	Q5MNZ9	HPRD
P03372	Q5QJE6	HPRD
P03372	Q5SRQ6	HPRD
P03372	Q5T2N8	IntAct
P03372	Q5THJ4	IntAct
P03372	Q6P3W7	IntAct
P03372	Q6PJG2	IntAct
P03372	Q6PKG0	IntAct
P03372	Q6PL18	HPRD; DIP
P03372	Q6PML9	HPRD
P03372	Q6STE5	HPRD
P03372	Q6ZVX7	IntAct
P03372	Q71RC2	IntAct
P03372	Q7L2E3	IntAct
P03372	Q7Z2W4	IntAct
P03372	Q7Z3K2	MINT
P03372	Q7Z406	IntAct
P03372	Q86TE4	IntAct
P03372	Q86U06	HPRD
P03372	Q86U70	HPRD
P03372	Q86UE4	IntAct
P03372	Q86VZ2	IntAct
P03372	Q86YN6	HPRD
P03372	Q8IWR1	HPRD
P03372	Q8IXJ9	IntAct
P03372	Q8IY81	IntAct
P03372	Q8IYB3	IntAct
P03372	Q8IZL8	HPRD; IntAct
P03372	Q8N1N5	IntAct
P03372	Q8N201	IntAct
P03372	Q8N895	IntAct
P03372	Q8NHW5	IntAct
P03372	Q8NI08	HPRD
P03372	Q8NI36	IntAct
P03372	Q8TAQ2	MINT
P03372	Q8TD17	HPRD
P03372	Q8TDD1	IntAct;HPRD
P03372	Q8WUY1	IntAct
P03372	Q8WV24	BioGRID
P03372	Q8WVV4	IntAct
P03372	Q8WX92	HPRD
P03372	Q8WY22	IntAct
P03372	Q92552	IntAct
P03372	Q92569	HPRD
P03372	Q92665	IntAct
P03372	Q92731	HPRD; IntAct
P03372	Q92769	IntAct
P03372	Q92841	IntAct
P03372	Q92900	IntAct
P03372	Q92905	HPRD
P03372	Q92956	HPRD
P03372	Q92993	HPRD
P03372	Q969G3	HPRD
P03372	Q969Q0	IntAct
P03372	Q96AQ6	IntAct
P03372	Q96CW1	IntAct
P03372	Q96DU9	IntAct
P03372	Q96EY7	IntAct
P03372	Q96GM5	IntAct
P03372	Q96GQ7	IntAct
P03372	Q96HI0	IntAct
P03372	Q96HR3	IntAct
P03372	Q96HS1	IntAct
P03372	Q96KM6	IntAct
P03372	Q96L73	HPRD
P03372	Q96L91	IntAct
P03372	Q96PK6	IntAct
P03372	Q96RI1	IntAct;HPRD
P03372	Q96SB4	IntAct
P03372	Q96T76	HPRD
P03372	Q99575	IntAct
P03372	Q99623	HPRD; IntAct
P03372	Q99729	IntAct
P03372	Q99933	HPRD
P03372	Q99966	HPRD; IntAct
P03372	Q9BQ39	IntAct
P03372	Q9BQ69	IntAct
P03372	Q9BQG0	IntAct
P03372	Q9BRD0	IntAct
P03372	Q9BT30	IntAct
P03372	Q9BTC8	MINT
P03372	Q9BTK6	MINT
P03372	Q9BUJ2	IntAct
P03372	Q9BV38	IntAct
P03372	Q9BVJ6	IntAct
P03372	Q9BVP2	IntAct
P03372	Q9BZE4	IntAct
P03372	Q9GZR2	HPRD
P03372	Q9H0A0	IntAct
P03372	Q9H1R3	IntAct
P03372	Q9H293	IntAct
P03372	Q9H3U1	IntAct
P03372	Q9H467	HPRD; IntAct; MINT
P03372	Q9HAV0	IntAct
P03372	Q9HBD4	HPRD
P03372	Q9HBH9	HPRD
P03372	Q9HCD5	IntAct
P03372	Q9HCL0	BioGRID
P03372	Q9HCM4	IntAct
P03372	Q9NPD3	IntAct
P03372	Q9NPJ4	HPRD; MINT
P03372	Q9NPJ6	IntAct
P03372	Q9NQU5	HPRD
P03372	Q9NQZ2	IntAct
P03372	Q9NR30	IntAct
P03372	Q9NVC6	IntAct
P03372	Q9NVI7	IntAct
P03372	Q9NVP1	IntAct
P03372	Q9NVW2	HPRD
P03372	Q9NW13	IntAct
P03372	Q9NX58	IntAct
P03372	Q9NXC2	BioGRID
P03372	Q9NYF8	IntAct
P03372	Q9NZ01	IntAct
P03372	Q9NZW4	BioGRID
P03372	Q9P035	IntAct
P03372	Q9P225	IntAct
P03372	Q9UBK2	HPRD
P03372	Q9UBL3	IntAct
P03372	Q9UBS4	IntAct
P03372	Q9UBS8	HPRD
P03372	Q9UGU0	HPRD
P03372	Q9UKW4	IntAct
P03372	Q9UM54	IntAct
P03372	Q9UN36	IntAct
P03372	Q9UN86	IntAct
P03372	Q9UNE7	HPRD
P03372	Q9UPP5	BioGRID
P03372	Q9UQ13	IntAct
P03372	Q9UQ35	IntAct
P03372	Q9Y230	IntAct
P03372	Q9Y265	IntAct
P03372	Q9Y294	IntAct
P03372	Q9Y2R5	IntAct
P03372	Q9Y2W1	IntAct
P03372	Q9Y2X3	IntAct
P03372	Q9Y399	IntAct
P03372	Q9Y3R0	IntAct; MINT
P03372	Q9Y3U8	IntAct
P03372	Q9Y4A5	HPRD
P03372	Q9Y4P3	IntAct
P03372	Q9Y5A9	IntAct
P03372	Q9Y5B9	IntAct
P03372	Q9Y618	HPRD
P03372	Q9Y6C7	HPRD; MINT
P03372	Q9Y6C9	HPRD
P03372	Q9Y6Q9	HPRD; IntAct
P03372	Q9Y6X2	HPRD; DIP

PTMD Annotation Information

※ Protein Information

Functional Description

Fasta Sequence

※ PTM-Disease Association

※ Disease Cross-ref Annotation

※ PTM Sites

※ Protein-Protein Interaction